Skip to main content

Sandoz decides on Basel for headquarters

| News

Sandoz decides on Basel for headquarters

01.06.2023

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected to take place in the second half of 2023. Sandoz plans to move from the Novartis campus to its new headquarters in the center in mid-2024.

Sandoz CEO Richard Saynor values Basel as "a global center for the life sciences industry" (image: Sandoz)

Sandoz AG, which specializes in generics and biosimilars, will set up its permanent headquarters in the center of Basel after separating from Novartis in future. According to a press release, Sandoz will move its headquarters from the Novartis campus to the Elsässertor office building in the center of Basel next to the train station after the separation in mid-2024.

CEO of Sandoz Richard Saynor stated in a press release that he is delighted that the company will continue to call Basel its home. He adds: “Our planned location in the heart of the city will allow us to create a working environment that meets our business needs and reflects our identity, culture, and values. Basel is a global center for the life sciences industry, attracting an unrivalled pool of talent and experience that will help us to grow further and achieve our ambition of being the sustainable global leader in generics and biosimilars.”

New working environment

The move will have no effect on the management of Sandoz’s global business according to the information provided. The new working environment will be designed to enable close collaboration and teamwork across the entire organization.

The pharmaceutical company Novartis announced its intention to separate from Sandoz in August 2022. At Novartis, Sandoz was led as a division for patent-free drugs. The planned separation is expected to take place in the second half of 2023. As an independent company, Sandoz will then list on the SIX Swiss Exchange.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Do you have a question? We'd like to hear from you.